We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Studies on Epstein-Barr Virus Aided by New Mouse Model

By Biotechdaily staff writers
Posted on 16 Sep 2004
Researchers studying the long-term effects of infection by Epstein-Barr virus have developed a transgenic mouse model that will enable experiments to be conducted that may clarify how Epstein-Barr proteins interact with cells of the immune system.

Investigators at the University of Iowa (Iowa City, USA) developed a mouse line that expresses the Epstein-Barr latent membrane protein 1 (LMP1). More...
LMP1 mimics the action of a normal human protein called CD40 that is associated with B cell signaling. In humans, LMP1 is produced when the latent virus becomes activated in individuals with suppressed immune systems. "The viral protein is an amazing mimic of the normal protein but, in a way, the viral protein does its functions too well,” explained senior author Dr. Gail Bishop, professor of microbiology at the University of Iowa. "The viral protein causes abnormal survival and activation of these B cells.”

Results from preliminary experiments with the new mouse model were published in the August 2004 issue of Immunity. The transgenic mice were found to produce excess autoantibodies as well as having certain problems with how cells are organized in the lymph nodes and spleen.

"Mice cannot be infected with Epstein-Barr because they do not have the receptor for this virus. What we have done is express in the mouse the most important transforming protein that is involved in the virus in humans,” said Dr. Bishop. "If the viral protein causes B cells to be hyperactive, this might increase the propensity of the small number of autoreactive B cells, which we all have, to become hyperactivated.”



Related Links:
University of Iowa

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.